Temasek Holdings
ABCL icon

Temasek Holdings’s AbCellera Biologics ABCL Stock Holding History

Temasek Holdings’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-281,729
Closed -$3M – 82
2022
Q2 		$3M Buy
+281,729
New +$2.39M 0.02% 82
2021
Q4 		– Sell
-246,907
Closed -$4.95M – 96
2021
Q3 		$4.95M Buy
246,907
+10,109
+4% +$179K 0.02% 72
2021
Q2 		$5.21M Buy
+236,798
New +$6.53M 0.02% 79

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Temasek Holdings's ABCL Position: Q3 2022 in Review

Temasek Holdings sold out of AbCellera Biologics (ABCL) in Q3 2022, closing a stake of 281,729 shares — an estimated $3M sold.

Temasek Holdings first reported a position in ABCL in Q2 2021 and held it in 3 quarters. The position peaked at $5.21M in Q2 2021. 190 funds tracked by Wall St. Rank hold ABCL as of Q3 2022.

  • Temasek Holdings reported no remaining AbCellera Biologics position as of Q3 2022 after selling out during the quarter.
  • Temasek Holdings sold 281,729 AbCellera Biologics shares in Q3 2022, an estimated $3M.
  • Temasek Holdings first reported a position in AbCellera Biologics in Q2 2021 and held it in 3 quarters.
  • Temasek Holdings's AbCellera Biologics position peaked at $5.21M in Q2 2021.
  • 190 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2022.

Based on Temasek Holdings's 13F filing for Q3 2022, filed 14 Nov 2022.